ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2375

Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7

Shoichi Fukui1, Haruna Matsuo2, Kanako Kojima3, Shota Kurushima1, Tohru Michitsuji4, Yoshika Tsuji5, Toshimasa Shimizu3, Masataka Umeda3, Remi Sumiyoshi5, Takashi Igawa1, Tomohiro Koga5, Shin-ya Kawashiri1, Naoki Iwamoto1, Tomoki Origuchi1 and Atsushi Kawakami1, 1Nagasaki University, Nagasaki, Japan, 2Nagasaki University, Nagasaki City, Japan, 3Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan, 5Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan

Meeting: ACR Convergence 2023

Keywords: ANCA, ANCA associated vasculitis, cytokines, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2370–2386) Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Interleukin 7 (IL-7) is a hematopoietic growth factor produced by stromal cells in the bone marrow and thymus, which is indispensable in maintaining immune cells. The transcriptome analysis using CD8 positive T cells demonstrated genes involved in the IL-7 receptor pathway were the poor prognostic factor in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) (McKinney EF, Nat Med 2010;16:586–91). However, the clinical utility of the serum IL-7 levels in AAV is unknown. We aimed to elucidate the clinical characteristics of patients with AAV with high serum IL-7 levels.

Methods: We retrospectively analyzed 60 patients newly diagnosed with AAV (granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)) from March 2010 to April 2022 with preserved sera. We collected medical records from baseline variables at diagnosis, including clinical symptoms, laboratory data, treatments, and outcomes. Multiplex cytokine and chemokine bead assays were performed using preserved serum supernatants. Serum samples from 101 healthy donors were used to define the normal serum IL-7 levels. We compared clinical indices between the patients with and without high levels of IL-7 defined by the median levels of serum IL-7.

Results: The median serum levels of IL-7 were 8.3pg/mL (IQR: 5.3pg/mL – 15.1pg/mL) and 22.4pg/mL (IQR: 11.9pg/mL – 46.6pg/mL) in healthy donors and patients with AAV, respectively. The median levels of IL-7 (22.4pg/mL) divided the patients with AAV into two groups (30 patients for each group). The IL-7 high group had significantly higher total Birmingham Vasculitis Activity Score (BVAS), higher white blood cell count, higher neutrophil count, higher platelet count, higher CRP level, lower lymphocyte count, and lower IgG levels compared to the IL-7 low group (Table). The serum levels of IL-7 correlated with the total BVAS score significantly (ρ=0.28 (Spearman’s rank correlation coefficient), p=0.028). No significant differences were shown in the type of ANCA (MPO-ANCA or PR3-ANCA) and the diseases (GPA or MPA). There were no differences in the treatments (initial prednisolone dose, methylprednisolone pulse therapy, intravenous cyclophosphamide, and rituximab) and the prognosis (relapse and death). The log-rank test demonstrated no significant differences in the survival rate (p=0.20, Figure).

Conclusion: The high serum levels of IL-7 at diagnosis demonstrated the high disease activity and distinct character with higher white blood cell count, platelet count, and CRP levels in AAV.

Supporting image 1

Table: Clinical characteristics of AAV with low and high levels of serum IL-7

Supporting image 2

Figure: Survival provability of AAV with low and high levels of serum IL-7


Disclosures: S. Fukui: None; H. Matsuo: None; K. Kojima: None; S. Kurushima: None; T. Michitsuji: None; Y. Tsuji: None; T. Shimizu: None; M. Umeda: None; R. Sumiyoshi: None; T. Igawa: None; T. Koga: None; S. Kawashiri: None; N. Iwamoto: None; T. Origuchi: None; A. Kawakami: None.

To cite this abstract in AMA style:

Fukui S, Matsuo H, Kojima K, Kurushima S, Michitsuji T, Tsuji Y, Shimizu T, Umeda M, Sumiyoshi R, Igawa T, Koga T, Kawashiri S, Iwamoto N, Origuchi T, Kawakami A. Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7 [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/clinical-characteristics-of-anca-associated-vasculitis-with-high-levels-of-serum-interleukin-7/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-of-anca-associated-vasculitis-with-high-levels-of-serum-interleukin-7/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology